Industry Insights

  1. Maximizing Efficiencies In Site Enrollment
    7/20/2018

    Pharma companies and CROs are recognizing the need for focused electronic feasibility solutions to resolve challenges with processes managed in Excel trackers.

  2. Which Door To RBM Adoption?
    7/18/2018

    Overcoming the many known barriers to adopting and implementing an RBM program.

  3. Companion Diagnostic Development: Current Trends And Recommendations
    7/12/2018

    Learn six strategies for success when developing your companion diagnostic.

  4. Age Diversity In Clinical Trials: Addressing The Unmet Need
    7/10/2018

    In a recent New York Times article, Paula Span raises the concern that elderly subjects are frequently omitted from clinical trials.  Consequently, physicians know very little about how a given treatment may affect their older patients.  Is a medication effective for the elderly?  Is it safe?  Without data, how is a physician to know?  

  5. The Importance Of Real World Evidence In Oncology
    7/9/2018

    There is a significant need to collect Real World Evidence (RWE) to demonstrate the benefit of these drugs in clinical practice which can then be used as the wrap around to demonstrate true clinical benefit and address all stakeholder needs.

  6. The Power Of The Central Laboratory For Immuno-Oncology Drug Development
    7/9/2018

    Sponsors who partner with a global central laboratory should expect optimized outcomes resulting from a depth of immuno-oncology and technological expertise and harmonized processes.

  7. Advances In Seasonal Influenza Vaccine Development
    7/9/2018

    Learn 6 critical ways to keep track of the flu to optimize your seasonal flu vaccine development clinical trials.

  8. What Motivates Patients To Participate In Multiple Clinical Trials?
    7/4/2018

    Successful clinical trial recruitment requires a thorough understanding of the target patient profile, and a key factor within this profile is patient motivation. What drives a patient to consider, then subsequently inquire, prescreen, and finally consent and participate in a trial? While these motivations will vary by previous research experience, indication or condition, study type, patient demographics, and other elements, common themes often emerge when one speaks to patients directly about their reasoning.

  9. Genomic Assays For Clinical Development: Identifying The Right Approach
    6/29/2018

    Learn more about different genomic assays that can be used during clinical development and which ones are right for your study.

  10. The End To End Importance Of Selecting The Right Biomarker In Cancer Studies
    6/29/2018

    A critical component in the fight against cancer and optimizing treatment outcomes for patients.